SBV Journal of Basic, Clinical and Applied Health Science

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  6 (2023)
Volume  5 (2022)
Volume  4 (2021)
Volume  3 (2020)
Volume  2 (2019)
Volume  1 (2018)
Related articles

VOLUME 3 , ISSUE 2 ( April-June, 2020 ) > List of Articles

REVIEW ARTICLE

COVID-19 Prophylaxis Using Hydroxychloroquine in India: A Review

Karthika P Subbaraj, Prathima A Chengani

Citation Information : Subbaraj KP, Chengani PA. COVID-19 Prophylaxis Using Hydroxychloroquine in India: A Review. 2020; 3 (2):80-82.

DOI: 10.5005/jp-journals-10082-02254

License: CC BY-NC 4.0

Published Online: 09-10-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was identified as the etiological agent for pneumonia of unknown cause, which broke out in 2019 in Wuhan city, China. The coronavirus disease (COVID-19) was considered as a pandemic by World Health Organization (WHO) and had caused significant panic globally. Hydroxychloroquine (HCQ) has been advised for prophylaxis against COVID-19 for the prevention of transmission by Indian Council of Medical Research (ICMR) based on in vitro studies conducted by National Institute of Virology (NIV), Pune. This article reviews the revised ICMR guidelines on the use of HCQ as prophylaxis against SARS-CoV-2, the proposed mechanism of HCQ prophylaxis, and its efficacy in COVID-19.

HTML PDF Share
  1. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. (Last visited: 25/5/2020).
  2. https://www.mohfw.gov.in/pdf/RevisedNationalClinical ManagementGuidelineforCOVID1931032020.pdf. (Last visited: 31/5/2020).
  3. https://www.business-standard.com/article/health/aiims-studying-effects-of-hcq-on-covid-19-patients-as-deaths-near-500-mark-120041800860_1.html (Last visited: 25/5/2020).
  4. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020;20(6):656–657. DOI: 10.1016/S1473-3099(20)30232-2.
  5. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020;6(1):16. DOI: 10.1038/s41421-020-0156-0.
  6. Lancet. COVID-19: protecting health-care workers. Lancet 2020;395(10228):922. DOI: 10.1016/S0140-6736(20)30644-9.
  7. https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf. (Last visited: 25/5/2020).
  8. https://www.icmr.gov.in/pdf/covid/techdoc/V5_Revised_advisory_on_the_use_of_HCQ_SARS_CoV2_infection.pdf (Last visited: 25/5/2020).
  9. Pranab C, Tanu A, Jitenkumar SK, et al. Healthcare workers & SARS-CoV-2 infection in India: a case-control investigation in the time of COVID-19. Indian J Med Res 2020. [Downloaded free from http://www.ijmr.org.in on Sunday, May 31, 2020, IP: 157.50. 15.78].
  10. Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Int J Antimicrob Agents 2020(6):105988. DOI: 10.1016/j.ijantimicag.2020.105988.
  11. Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis 2020;S1473-3099(20):30313–30313. DOI: 10.1016/S1473-3099(20) 30313-3.
  12. Tilangi P, Desai D, Khan A, Soneja M. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach. Lancet Infect Dis 2020;S1473-3099(20):30430–30438. DOI: 10.1016/S1473-3099(20)30430-8.
  13. Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis 2020;S1473-3099(20):30296–30296.
  14. Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev 2020(4):CD013587. DOI: 10.1002/14651858.CD013587.
  15. Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). Int J Rheum Dis 2020;00(5):1–7. DOI: 10.1111/1756-185X.13842.
  16. https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf.
  17. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–1034. DOI: 10.1016/S0140-6736(20)30628-0.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.